Anthropic and Claude Healthcare Breakthroughs: Timeline

In 2025 Anthropic was selling Claude to drugmakers. By late 2026 it was running its own biology lab and starting its own drug programs. This page logs every health and life sciences move by Anthropic that we could source, and grades each result on the same evidence scale we use for every AI lab.

Presented By Our Partners

The short answer: Anthropic has built Claude into tools for researchers, clinicians and drugmakers, signed deals with Genmab, Bristol Myers Squibb and Novo Nordisk, bought Coefficient Bio and Mithril, confirmed its own wet lab and started its own drug programs. Its biggest results, an enzyme system resembling CRISPR that it says Claude found and protein binders designed by Claude that passed lab tests, are company-reported. We found no peer-reviewed paper or human trial for an Anthropic health or drug result as of October 28, 2026.

Tier: Tier 1, frontier lab. Its own wet lab and drug programs now overlap with tier 2 work.
Own models: Yes, the general-purpose Claude models. We found no biology-specific Anthropic model.
Own wet lab: Yes (San Francisco Bay Area, confirmed September 2026)
First health move: October 20, 2025: Claude for Life Sciences, its first dedicated life sciences product
Furthest result so far: Company-reported, Molecule design
Key partners: Genmab, Bristol Myers Squibb, Novo Nordisk, HealthEx

What Has Anthropic Done in Healthcare?

Anthropic has spent about a year turning Claude, a general-purpose AI model, into a research and operations tool for drugmakers and health systems, then added its own lab and its own drug programs. Most of its health record so far is products, deals and hires. The scientific results it has shared are company-reported and early stage.

The first phase was tools. Claude for Life Sciences launched on October 20, 2025, aimed at biotech and pharma teams, as SiliconANGLE reported. R&D World reported that it outperformed humans at lab protocol tasks and cut pharma documentation time, figures that came from Anthropic. In January 2026 Genmab announced a partnership to use Anthropic’s agentic AI in research and development, per its press release. On January 11, Anthropic launched Claude for Healthcare and partnered with HealthEx so users can connect their medical records, according to Fortune. Fierce Healthcare reported that the launch at the J.P. Morgan Healthcare Conference targeted health systems and payers.

The second phase was buying expertise. In April 2026 Anthropic acquired Coefficient Bio, a stealth AI startup, in a deal Fierce Biotech reported at $400 million. Novartis CEO Vas Narasimhan joined its board. In May, Bristol Myers Squibb announced a strategic agreement to make Claude Enterprise a shared platform across its global operations, according to the company’s press release. In June, AlphaFold co-creator John Jumper said he would leave Google DeepMind for Anthropic, as Bloomberg Government reported.

The third phase is its own science. On June 30, 2026, Anthropic released Claude Science, a product aimed at researchers and the pharma industry, as STAT reported. It published protein design work in which Claude’s binders passed lab tests. In September it confirmed a Bay Area wet lab, which Reuters reported it set up as it ramps an AI drug program (via The Star), announced an enzyme system it says Claude found and partnered with Novo Nordisk. In October it published a report on drug development work with six partner companies and bought Mithril, a one-person biotech, to start its own drug programs, as The Next Web reported.

Anthropic Healthcare Timeline: Every Move Since 2025

Date	Move	Type	Evidence level	Source
Oct 2026	Acquired Mithril, a one-person biotech, and started its own drug programs	Acquisition	Not a result	The Next Web
Oct 2026	Published a report on early drug development work with six partner companies; coverage cites an 89% cut in drug development paperwork time and cancer-fighting cells that worked longer in lab tests	Result	Company-reported, Molecule design	Anthropic
Sep 23, 2026	Announced an enzyme system resembling CRISPR that it says Claude found after scanning about 200,000 enzymes	Result	Company-reported, Research tool	TechCrunch
Sep 18, 2026	Confirmed a Bay Area wet lab that runs biology experiments	Lab	Not a result	TechCrunch
Sep 16, 2026	Partnered with Novo Nordisk to speed up drug development with Claude	Partnership	Not a result	BNN Bloomberg
Aug 2026	Reported that Claude designed protein binders against 14 of 15 targets that passed lab tests, and released the dataset	Result	Company-reported, Molecule design	Anthropic
Jun 30, 2026	Released Claude Science, a product aimed at researchers and the pharma industry	Product	Not a result	STAT
Jun 2026	AlphaFold co-creator and Nobel laureate John Jumper said he would leave Google DeepMind for Anthropic	Hire	Not a result	Bloomberg Government
May 20, 2026	Signed a strategic agreement with Bristol Myers Squibb to make Claude Enterprise a shared platform across its global operations	Partnership	Not a result	BioSpace
Apr 2026	Added Novartis CEO Vas Narasimhan to its board	Hire	Not a result	Anthropic
Apr 2026	Acquired Coefficient Bio, a stealth AI startup, for a reported $400 million	Acquisition	Not a result	Fierce Biotech
Jan 11, 2026	Launched Claude for Healthcare and partnered with HealthEx to let users connect medical records	Product	Not a result	Fortune
Jan 7, 2026	Genmab partnered with Anthropic to use agentic AI in research and development	Partnership	Not a result	Business Wire
Oct 20, 2025	Launched Claude for Life Sciences for biotech and pharma research teams	Product	Not a result	Anthropic

Anthropic’s Biggest Results, and How Far Each Has Been Proven

None of Anthropic’s health or biology results has passed peer review or been tested in people yet. Every result below is company-reported, which is the second of five levels on our scale.

The enzyme system resembling CRISPR (September 2026). Anthropic says Claude found a new enzyme system that resembles the gene editing tool CRISPR, as Smithsonian Magazine reported, and investingLive reported that Claude scanned 200,000 enzymes to find it. A resemblance to CRISPR is not the same as a working editing tool. Evidence level: Company-reported. Stage: Research tool. What would prove it next: a peer-reviewed paper, and an outside lab confirming the enzymes work as described.

Protein binders designed by Claude (August 2026). Anthropic reported that Claude designed protein binders that were then validated in lab tests, as eWeek summarized. AI Weekly reported binders against 14 of 15 protein targets, and Anthropic released the dataset behind the run, which lets outside groups check the work. A binder that sticks to a target in a lab assay is a starting point, not a drug. Evidence level: Company-reported. Stage: Molecule design. What would prove it next: peer review, an independent group reproducing the binder results, and binders tested in a disease model.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Partner drug development work (October 2026). Anthropic’s report on early progress in drug development describes work with six partner companies, per Crypto Briefing. Coverage reports that Claude cut drug development paperwork time by 89% (Upstox) and helped cancer-fighting cells work longer in lab tests (WinBuzzer). The headlines we could verify do not say which partner produced which result. Evidence level: Company-reported. Stage: Molecule design (the cancer work) and Operations (the paperwork). What would prove it next: data published by the partners themselves, and a named Claude-assisted molecule entering preclinical development. Our progress check on Anthropic’s partner results grades each result in detail.

Life sciences benchmarks and documentation time (October 2025). At the Claude for Life Sciences launch, R&D World reported Anthropic figures showing Claude outperforming humans on lab protocol tasks and reducing pharma documentation time. Evidence level: Company-reported. Stage: Operations. What would prove it next: an independent evaluation measuring time saved and error rates in regulated documents.

What PubMed shows. A PubMed search for Anthropic affiliations found Anthropic staff on papers outside health, and one Anthropic co-author on a short Nature Medicine piece titled “Toward a test of medical AI superintelligence,” written with researchers from Stanford, Harvard, Google, OpenAI, Microsoft, Amazon and ARPA-H, among others (PMID 42509372). It does not report a result. We found no peer-reviewed paper reporting an Anthropic health or drug result.

Who Anthropic Works With

Anthropic works mainly with large drugmakers as enterprise customers, plus one health records company. It owns its lab and has made two life sciences acquisitions.

Pharma customers and partners: Genmab (partnership, January 2026), Bristol Myers Squibb (strategic agreement, May 2026) and Novo Nordisk (partnership, September 2026).
Drug development report partners: six companies, per coverage of the October 2026 report. The headlines we could verify do not name them.
Health records: HealthEx, which lets Claude for Healthcare users connect their medical records.
Acquisitions: Coefficient Bio (April 2026, reported $400 million) and Mithril (October 2026), a one-person biotech bought as Anthropic started its own drug programs.
Governance and talent: Novartis CEO Vas Narasimhan on the board; John Jumper joining from Google DeepMind.
Own lab: Yes, in the San Francisco Bay Area, as TechCrunch and AI Weekly reported.

What to Watch Next

A peer-reviewed paper on the enzyme system, and whether an outside lab confirms it.
An independent replication of the protein binder results using Anthropic’s released dataset.
The first named target or candidate from Anthropic’s in-house drug programs, and whether any enters preclinical development.
The six report partners named, with data each one publishes on what Claude changed in a specific program.
A prospective study of Claude for Healthcare in a clinical setting that reports error rates or patient outcomes.

What This Means for You

If you are a patient, nothing Anthropic has done changes the treatments available to you today. Its drug programs are early, and none has reached a human trial. Claude for Healthcare can help you organize and understand your own records if you connect them, but it is not a diagnosis tool that has been tested in patient trials.

If you work in research or care, Claude is already licensed at several large drugmakers. Ask what each use was validated on and who checks the output before it touches a regulated decision. Treat the enzyme and protein results as promising leads until they pass peer review and outside replication, and judge Anthropic’s in-house drug programs by the same milestones as any biotech: a named target, animal data and a filing to start human trials.

Compiled by Healthcare Discovery from company announcements, named news reports and PubMed. Every PMID on this page was checked against PubMed on October 28, 2026. Evidence levels follow the scale explained in our AI healthcare breakthroughs tracker. Healthcare Discovery uses AI research tools from several companies on this page, including OpenAI, Anthropic and Google models; no company listed reviewed or paid for this page.

What has Anthropic done in healthcare?

Anthropic launched Claude for Life Sciences in October 2025 and Claude for Healthcare in January 2026, signed deals with Genmab, Bristol Myers Squibb and Novo Nordisk, acquired Coefficient Bio in April 2026, launched Claude Science in June 2026, confirmed its own Bay Area wet lab in September 2026 and bought Mithril in October 2026 as it started its own drug programs.

Is Claude used in drug discovery?

Yes. Drugmakers including Genmab, Bristol Myers Squibb and Novo Nordisk have agreements to use Claude in research and operations, and in October 2026 Anthropic reported early results from work with six partner companies, including an 89% cut in drug development paperwork time. These results are company-reported and have not been peer reviewed.

Does Anthropic have its own lab?

Yes. Anthropic confirmed a wet lab in the San Francisco Bay Area in September 2026. Days later it announced an enzyme system resembling CRISPR that it says Claude found.

Has Claude discovered a new drug?

No. As of October 2026, Claude has helped find an enzyme system and design protein binders that passed lab tests, both company-reported. Anthropic’s own drug programs are early and none has entered a human trial.

What is Claude for Healthcare?

Claude for Healthcare is a set of Claude tools launched in January 2026 for health systems, payers and consumers. Through a partnership with HealthEx, users can connect their medical records to Claude.

Has an AI-designed drug been approved?

Not as of October 2026. Several AI-designed drug candidates are in clinical trials, but none has received FDA approval.

Sources

Goh E, et al. Toward a test of medical AI superintelligence. Nature Medicine, 2026. PMID 42509372
The Next Web. Anthropic buys a one-person biotech and starts its own drug programmes, October 2026. The Next Web
Anthropic. Early progress on accelerating drug development with Claude, October 2026. Anthropic
Crypto Briefing. Anthropic partners with six companies to push Claude into drug discovery, October 2026. Crypto Briefing
Upstox. Claude shows promise in cancer research, cuts drug development paperwork by 89%: Anthropic, October 2026. Upstox
WinBuzzer. Anthropic’s Claude AI helped boost cancer-fighting cells in lab tests, October 2026. WinBuzzer
TechCrunch. Anthropic says its biology lab has already found something big, September 2026. TechCrunch
Smithsonian Magazine. Anthropic says its AI discovered a new enzyme system that resembles the revolutionary gene editing technology CRISPR, September 2026. Smithsonian Magazine
investingLive. Anthropic’s Claude uncovers CRISPR-like enzyme system after scanning 200,000 enzymes, September 2026. investingLive
TechCrunch. Anthropic is operating a lab that conducts biology experiments, September 2026. TechCrunch
The Star (Reuters). Exclusive: Anthropic quietly sets up biology lab as it ramps AI drug program, September 2026. The Star
AI Weekly. Anthropic Confirms Bay Area Wet Lab for Biology Experiments, September 2026. AI Weekly
BNN Bloomberg. Novo partners with Anthropic to speed up drug development with Claude, September 2026. BNN Bloomberg
Anthropic. Claude accelerates protein design, August 2026. Anthropic
eWeek. Anthropic says Claude designed protein binders validated in lab tests, August 2026. eWeek
AI Weekly. Anthropic Says Claude Designed Binders Against 14 of 15 Protein Targets, Beating Typical 10-15% Hit Rate, 2026. AI Weekly
AI Weekly. Anthropic releases dataset behind Claude’s 14/15 binder run, 2026. AI Weekly
STAT. Anthropic releases Claude Science, a product aimed at researchers, the pharma industry, June 2026. STAT
Bloomberg Government. Nobel winner John Jumper to leave Google DeepMind for Anthropic, June 2026. Bloomberg Government
BioSpace. Bristol Myers Squibb announces strategic agreement with Anthropic to position Claude Enterprise as the shared intelligence platform across its global operations, May 2026. BioSpace
Anthropic. Vas Narasimhan joins Anthropic’s board, April 2026. Anthropic
Fierce Biotech. Anthropic acquires stealth AI startup Coefficient Bio in $400M deal: reports, April 2026. Fierce Biotech
Fortune. Anthropic unveils Claude for Healthcare and expands life science features, partners with HealthEx to let users connect medical records, January 2026. Fortune
Fierce Healthcare. JPM26: Anthropic launches Claude for Healthcare to turbocharge AI efficiency at health systems, payers, January 2026. Fierce Healthcare
Business Wire. Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence, January 2026. Business Wire
Anthropic. Claude for Life Sciences, October 2025. Anthropic
SiliconANGLE. Anthropic takes aim at biotech with Claude for Life Sciences, October 2025. SiliconANGLE
R&D World. Anthropic unveils Claude for Life Sciences, which reportedly outperforms humans at lab protocol tasks and slashes pharma documentation time, October 2025. R&D World

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

No spam. Unsubscribe anytime. We respect your inbox.